Response to crizotinib treatment for ROS1 p.H1999N mutation and secondary EGFR p.V774M mutation after drug resistance: a Case Report
Yongmei Liu
Genetic fusion involving the ROS1 gene lead to the constitutive activation of its encoded tyrosine kinase, thereby acting as an oncogenic driver that promotes tumor cell proliferation. Numerous missense mutations in ROS1 are currently classified as variants of unknown significance, especially, mutations in kinase domain are crucial mediators of the resistance of ROS1 fusion-positive cancers to ROS1 tyrosine kinase inhibitors (TKIs). This study presents a rare case of a ROS1 p.H1999N mutation pos